COMy 2019 | Rationale for NK-cell therapy in myeloma
Michael O’Dwyer
• 17 May 2019
Here, Michael O’Dwyer, MD, PhD, from the National University of Ireland, Galway, Ireland, discusses the importance of fully functional NK-cells, which mediate antibody-dependant cytotoxicity, in multiple myeloma. At the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France, Prof. O’Dwyer also speaks of the challenges of CAR T-cell administration as a therapy, and how anti-CD38 CAR NK-cells could selectively target myeloma cells.
